Severe sepsis and therapy with activated protein C

New England Journal of Medicine

Volumn 353, Issue 13, 2005, Pages 1398-1400

  Parrillo, Joseph E ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIINFECTIVE AGENT;

BIOLOGICAL MONITORING; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFECT; EDITORIAL; HUMAN; KIDNEY TRANSPLANTATION; LUNG; MICROORGANISM; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURGICAL DRAINAGE;

ANTI-INFECTIVE AGENTS; APACHE; DRUG APPROVAL; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; TREATMENT FAILURE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 25444519445     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058160     Document Type: Editorial

References (12)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-7.
3. Parrillo JE. Idem. Shock syndromes related to sepsis. In: Goldman L, Ausiello D, eds. Cecil textbook of medicine. 22nd ed. Philadelphia: W.B. Saunders, 2004:620-6.
4. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73. [Errata, Crit Care Med 2004;32:1448, 2169-70.]
5. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
6. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31:12-9.
7. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002;347:1027-30.
8. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002;347:1030-4.
9. Abraham E, Laterre P-F, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41.
10. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002;347:993-1000.
11. Angus DC, Laterre PF, Helterbrand J, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004;32:2199-206.
12. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med (in press).